CULLINAN THERAPEUTICS, INC. Financing Cash Flow
CULLINAN THERAPEUTICS, INC. (CGEM) reported Financing Cash Flow of $1.48 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- CULLINAN THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $1.10M, a 194.91% increase year-over-year.
- CULLINAN THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $380.00K.
- CULLINAN THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $715.00K, a 54.80% decline year-over-year.
- CULLINAN THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- CULLINAN THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $1.09M, a 99.59% decline from fiscal 2024.
- CULLINAN THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $266.19M, a 553.21% increase from fiscal 2023.
- CULLINAN THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $40.75M.
- CULLINAN THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2022 was -$25.93M, a 109.65% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.48M 10-Q · filed 2026-08-06 | $2.19M derived: sum of 3 quarters · filed 2026-08-06 | $2.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $380.00K 10-Q · filed 2026-05-07 | $1.09M derived: sum of 2 quarters · filed 2026-05-07 | $1.09M derived: sum of 3 quarters · filed 2026-05-07 | $1.47M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $715.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $715.00K derived: sum of 2 quarters · filed 2026-03-10 | $1.09M derived: sum of 3 quarters · filed 2026-08-06 | $1.09M 10-K · filed 2026-03-10 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $373.00K derived: sum of 2 quarters · filed 2026-08-06 | $373.00K 10-Q · filed 2025-11-06 | $1.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $373.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $373.00K 10-Q · filed 2026-08-06 | $1.96M derived: sum of 3 quarters · filed 2026-08-06 | $3.28M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $1.58M derived: sum of 2 quarters · filed 2026-05-07 | $2.91M derived: sum of 3 quarters · filed 2026-05-07 | $265.10M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $2.91M derived: sum of 2 quarters · filed 2026-03-10 | $265.10M derived: sum of 3 quarters · filed 2026-03-10 | $266.19M 10-K · filed 2026-03-10 |
| 2024-09-30 | $1.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $263.52M derived: sum of 2 quarters · filed 2025-11-06 | $264.61M 10-Q · filed 2025-11-06 | $264.85M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $262.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $263.28M 10-Q · filed 2025-08-07 | $263.53M derived: sum of 3 quarters · filed 2025-08-07 | $263.64M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.08M 10-Q · filed 2025-05-08 | $1.33M derived: sum of 2 quarters · filed 2025-05-08 | $1.45M derived: sum of 3 quarters · filed 2025-05-08 | $40.05M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $248.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $360.00K derived: sum of 2 quarters · filed 2025-02-27 | $38.96M derived: sum of 3 quarters · filed 2025-02-27 | $40.75M 10-K · filed 2025-02-27 |
| 2023-09-30 | $112.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $38.71M derived: sum of 2 quarters · filed 2024-11-07 | $40.50M 10-Q · filed 2024-11-07 | $7.59M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $38.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $40.39M 10-Q · filed 2024-08-08 | $7.48M derived: sum of 3 quarters · filed 2024-08-08 | $8.90M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.79M 10-Q · filed 2024-05-15 | -$31.12M derived: sum of 2 quarters · filed 2024-05-15 | -$29.70M derived: sum of 3 quarters · filed 2024-05-15 | -$27.68M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$32.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$31.49M derived: sum of 2 quarters · filed 2024-03-14 | -$29.47M derived: sum of 3 quarters · filed 2024-03-14 | -$25.93M 10-K · filed 2024-03-14 |
| 2022-09-30 | $1.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $3.44M derived: sum of 2 quarters · filed 2023-11-08 | $6.98M 10-Q · filed 2023-11-08 | $9.68M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $2.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $5.55M 10-Q · filed 2023-08-10 | $8.26M derived: sum of 3 quarters · filed 2023-08-10 | $8.84M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $3.54M 10-Q · filed 2023-05-11 | $6.24M derived: sum of 2 quarters · filed 2023-05-11 | $6.82M derived: sum of 3 quarters · filed 2023-05-11 | $7.75M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $3.28M derived: sum of 2 quarters · filed 2023-03-09 | $4.20M derived: sum of 3 quarters · filed 2023-03-09 | $268.78M 10-K · filed 2023-03-09 |
| 2021-09-30 | $579.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $1.50M derived: sum of 2 quarters · filed 2022-11-14 | $266.08M 10-Q · filed 2022-11-14 | $390.98M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $923.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $265.50M 10-Q · filed 2022-08-10 | $390.40M derived: sum of 3 quarters · filed 2022-08-10 | $391.61M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $264.58M 10-Q · filed 2022-05-16 | $389.48M derived: sum of 2 quarters · filed 2022-05-16 | $390.68M derived: sum of 3 quarters · filed 2022-05-16 | $390.68M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $124.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $126.10M derived: sum of 2 quarters · filed 2022-03-17 | $126.10M derived: sum of 3 quarters · filed 2022-03-17 | $140.14M 10-K · filed 2022-03-17 |
| 2020-09-30 | $1.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $1.21M derived: sum of 2 quarters · filed 2021-11-09 | $15.24M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $14.04M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $14.04M 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |